Keyhole-Limpet Hemocyanin

DRUG5 trials

Sponsors

Agouron Pharmaceuticals, National Institute of Allergy and Infectious Diseases (NIAID), Medical University of Graz, University of Oxford

Conditions

Chronic Hepatitis CHIV InfectionsImmune ResponseLiver Cirrhosis

Phase 1

Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC

CompletedNCT00026624

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2006-10-31Updated: 2021-11-01

Phase 4

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Agouron PharmaceuticalsHIV Infections

Start: 1999-12-31Target: 200Updated: 2005-06-24

Unknown Phase

Administration of Growth Hormone to Increase CD4+ Count in Patients Taking Anti-HIV Drugs

CompletedNCT00050921

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2005-03-31Target: 60Updated: 2021-11-01

Keyhole Limpet Hemocyanin in Chronic Hepatitis C

CompletedNCT01509391

Medical University of GrazChronic Hepatitis C, Liver Cirrhosis

Start: 2012-01-31End: 2012-10-31Updated: 2012-10-17

KLH Challenge to Explore the Human Immune Response

University of OxfordImmune Response

Start: 2023-03-01End: 2024-02-29Target: 39Updated: 2023-05-25